Skip to content

MRI Radiomics Combined With Pathomics on the Prediction of Molecular Classification and Prognosis of Endometrial Cancer

Study on the Prediction of Molecular Classification and Prognosis of Endometrial Cancer Using a Model Constructed by Magnetic Resonance Imaging Radiomics Combined With Pathomics

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06126393
Enrollment
350
Registered
2023-11-13
Start date
2024-01-01
Completion date
2027-06-30
Last updated
2023-11-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometrial Neoplasms

Keywords

Endometrial Neoplasms, machine learning, Radiomics, Pathomics, TCGA classification

Brief summary

Molecular typing provides accurate information for the diagnosis, treatment and prognosis prediction of endometrial cancer, which has important clinical significance. However, due to its high cost and complicated process, it is difficult to be widely used in clinical practice. Based on the artificial intelligence method, this study fused the characteristics of MRI radiomics and pathomics, combined with the clinical pathological information, built a model to predict the molecular typing and prognosis, analyzed the biological characteristics of endometrial cancer from the multi-scale level, guided the personalized and precise diagnosis and treatment, in order to improve the prognosis of patients.

Detailed description

In this project, 150 cases of endometrial cancer were retrospectively collected, and 200 cases of endometrial cancer will be prospectively collected. All patients were pathologically confirmed and underwent Promise molecular typing. Before treatment, all patients completed abdominal MRI. Based on artificial intelligence technology, image features were extracted from magnetic resonance imaging, pathological features were extracted from pathological data, and clinical pathological data were collected at the same time. The treatment effect, recurrence and metastasis of patients were followed up, and the five-year survival rate and five-year progression free survival rate were calculated. It is proposed to focus on the following research: 1. Construction of molecular typing and prognosis prediction model of endometrial cancer based on magnetic resonance imaging Radiomics 2. Construction of molecular typing and prognosis prediction model of endometrial cancer based on pathomics. 3. Construction of a prediction model for molecular typing of endometrial cancer by integrating pathomics and radiomics.

Interventions

DIAGNOSTIC_TESTnext generation sequencing AND Immunohistochemical examination

First, the mismatch repair (MMR) proteins were detected by immunohistochemistry, and the deletion of one or more proteins was classified as d-MMR subtype; Then the POLE gene mutation detection was performed, and the mutation Changes were classified as POLE mutation; Finally, p53 was detected by immunohistochemistry, and p53 mutant (p53 abn) and p53 wild-type (p53wt) were distinguished.

Sponsors

Fujian Provincial Hospital
CollaboratorOTHER
First Affiliated Hospital of Fujian Medical University
CollaboratorOTHER
Gutian Hospital
CollaboratorUNKNOWN
Fujian Cancer Hospital
Lead SponsorOTHER_GOV

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 80 Years

Inclusion criteria

* •Pathologically confirmed as endometrial malignant tumor with complete pathological H&E stained sections; * Age ≥ 18 years and ≤ 80 years; * No other malignant cancers was found; * The complete immunohistochemical and second-generation sequencing results can be used for the molecular typing of ProMisE; * Magnetic resonance examination was performed within 2 weeks before treatment, and there was at least one measurable lesion according to RECIST 1.1 Criteria.

Exclusion criteria

* • The image quality is poor or the tumor is too small due to serious graphic artifact and degeneration, and the ROI cannot be accurately delineated; * Patients who received any antitumor therapy before surgery; * Diagnostic endometrial biopsy before MRI

Design outcomes

Primary

MeasureTime frameDescription
Application of magnetic resonance imaging radiomics and pathomics to construct a model for predicting the molecular classification and prognosis of endometrial cancer2026-12-21The imaging and pathological features of endometrial cancer patients were extracted by artificial intelligence method. Combined with clinicopathological risk factors and survival time, an imaging nomogram was constructed by lasso regression method to predict the molecular classification and prognosis of endometrial cancer. ROC curve was used to evaluate the test efficiency of the model.

Secondary

MeasureTime frameDescription
Application of magnetic resonance imaging radiomics to construct a model for predicting the molecular classification and prognosis of endometrial cancer2026-12-21The imaging features of endometrial cancer patients were extracted by artificial intelligence method. Combined with clinicopathological risk factors and survival time, an imaging nomogram was constructed by lasso regression method to predict the molecular classification and prognosis of endometrial cancer. ROC curve was used to evaluate the test efficiency of the model.

Other

MeasureTime frameDescription
Application of pathomics to construct a model for predicting the molecular classification and prognosis of endometrial cancer2026-12-21The pathomics features of endometrial cancer patients were extracted by artificial intelligence method. Combined with clinicopathological risk factors and survival time, an imaging nomogram was constructed by lasso regression method to predict the molecular classification and prognosis of endometrial cancer. ROC curve was used to evaluate the test efficiency of the model.

Countries

China

Contacts

Primary ContactJian Chen, Master
marsz3@126.com15806030009

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026